Nabil G. Seidah, C.M., O.Q., PhD, FRSC
Dr. Seidah’s research focuses on a family of nine mammalian protein convertases (PCs): PC1, PC2, Furin, PC4, PC5, PACE4, PC7, SKI-1 and PCSK9. These enzymes are involved in the activation of hormone precursors, growth or transcription factors, receptors, or envelope proteins for pathogenic agents. His team is concentrating on the active mechanism and regulation of these enzymes, identifying their substrates and potential inhibitors. The goal of advancing our understanding of the physiological roles they play in cells and in mice is to develop clinical implications, as in the case of PCSK9. The team uses a broad range of techniques: protein and peptide biochemistry, enzymology, molecular and cell biology, proteomics and genetics. The lab possesses a unique collection of mutants and has completed full and/or conditional knockouts on PC5, Furin, PC7 and PCSK9. PCSK9 is a special target for attacking familial hypercholesterolemia. The role PC7 plays in the central nervous system appears to be connected to the development of anxiety, as mice whose PC7 (PCSK7) gene has been invalidated present with a tranquilizer phenotype. The key roles SKI-1 and PCSK9 play in cholesterol homeostasis have led the team to expand and to devote considerable efforts to developing pharmacological applications related to cardiovascular diseases.
Awards and honours
Degrees and relevant experience